TY - JOUR
T1 - Deliberation on Deferred Cytoreductive Nephrectomy and Postoperative Treatment for Advanced Renal Cell Carcinoma
T2 - A Case Report
AU - Nakagawa, Takuya
AU - Kawasaki, Yoshihide
AU - Sato, Satoko
AU - Katayama, Hiromichi
AU - Satake, Yohei
AU - Shimada, Shuichi
AU - Sato, Takuma
AU - Kawamorita, Naoki
AU - Yamashita, Shinichi
AU - Mitsuzuka, Koji
AU - Kohyama, Atsushi
AU - Ishida, Masaharu
AU - Ohtsuka, Hideo
AU - Unno, Michiaki
AU - Ito, Akihiro
N1 - Publisher Copyright:
© 2022 The Author(s). Published by S. Karger AG, Basel.
PY - 2022/11/8
Y1 - 2022/11/8
N2 - In a rare case, free from systemic therapy, deferred cytoreductive nephrectomy was implemented in treating an advanced renal cell carcinoma with liver, lung, and splenic colon metastases. A 59-year-old man diagnosed with advanced renal cell carcinoma underwent deferred cytoreductive nephrectomy due to a partial response to systemic treatment after a period of 1 year. After the surgery, no additional treatment was implemented. Furthermore, after 10 months, the patient had no recurrence of renal cell carcinoma. Through a review of this case and deferred cases in the current literature, we could emphasize the importance of image evaluation and pathological findings as an indication for surgery and subsequent treatment options. However, there is room for debate with regards to the indications for deferred cytoreductive nephrectomy as well as a therapeutic strategy after the surgery. This report discusses the significance of deferred cytoreductive nephrectomy in terms of prognosis and quality-of-life improvement in advanced renal cancer.
AB - In a rare case, free from systemic therapy, deferred cytoreductive nephrectomy was implemented in treating an advanced renal cell carcinoma with liver, lung, and splenic colon metastases. A 59-year-old man diagnosed with advanced renal cell carcinoma underwent deferred cytoreductive nephrectomy due to a partial response to systemic treatment after a period of 1 year. After the surgery, no additional treatment was implemented. Furthermore, after 10 months, the patient had no recurrence of renal cell carcinoma. Through a review of this case and deferred cases in the current literature, we could emphasize the importance of image evaluation and pathological findings as an indication for surgery and subsequent treatment options. However, there is room for debate with regards to the indications for deferred cytoreductive nephrectomy as well as a therapeutic strategy after the surgery. This report discusses the significance of deferred cytoreductive nephrectomy in terms of prognosis and quality-of-life improvement in advanced renal cancer.
KW - Cabozantinib
KW - Deferred cytoreductive nephrectomy
KW - Immunotherapy
KW - Renal cell carcinoma
KW - The Morphology Attenuation Size and Structure criteria
UR - http://www.scopus.com/inward/record.url?scp=85144513102&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144513102&partnerID=8YFLogxK
U2 - 10.1159/000527089
DO - 10.1159/000527089
M3 - Article
AN - SCOPUS:85144513102
SN - 1662-6575
VL - 15
SP - 1014
EP - 1020
JO - Case Reports in Oncology
JF - Case Reports in Oncology
IS - 3
ER -
